SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

03 May 2022 Evaluate
The March 2022 quarter revenue stood at Rs. 2821.42 millions, up 9.85% as compared to Rs. 2568.49 millions during the corresponding quarter last year.A comparatively good net profit growth of 25.03% to Rs. 867.09 millions was reported for the quarter ended March 2022 compared to Rs. 693.48 millions of previous same quarter.Operating Profit saw a handsome growth to 1106.76 millions from 967.68 millions in the quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 2821.42 2568.49 9.85 12157.30 11088.34 9.64 12157.30 11088.34 9.64
Other Income 90.52 27.48 229.40 289.89 99.98 189.95 289.89 99.98 189.95
PBIDT 1106.76 967.68 14.37 5129.84 4273.12 20.05 5129.84 4273.12 20.05
Interest 9.77 1.99 390.95 29.91 7.78 284.45 29.91 7.78 284.45
PBDT 1096.99 965.69 13.60 5099.93 4265.34 19.57 5099.93 4265.34 19.57
Depreciation 150.70 101.38 48.65 514.55 376.40 36.70 514.55 376.40 36.70
PBT 946.29 864.31 9.49 4585.38 3888.94 17.91 4585.38 3888.94 17.91
TAX 79.20 170.83 -53.64 413.46 382.89 7.98 413.46 382.89 7.98
Deferred Tax 6.24 4.72 32.20 -388.26 -318.95 21.73 -388.26 -318.95 21.73
PAT 867.09 693.48 25.03 4171.92 3506.05 18.99 4171.92 3506.05 18.99
Equity 135.93 135.78 0.11 135.93 135.78 0.11 135.93 135.78 0.11
PBIDTM(%) 39.23 37.68 4.12 42.20 38.54 9.49 42.20 38.54 9.49

Eris Lifesciences Share Price

1376.25 -16.55 (-1.19%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×